EMICIZUMAB DATA
Additional Topics
Select publications and scientific data presentations with the strongest and most relevant data are provided below.
Bone and Joint Health
Effect of Emicizumab Prophylaxis on Bone and Joint Health Markers in People with Haemophilia A Without Factor VIII Inhibitors in the HAVEN 3 Study
Kiialainen A, Niggli M, Kempton C, et al. Haemophilia. 2022;28(6):1033–1043.
Bone and Joint Health Markers in Persons With Hemophilia A (PwHA) Treated With Emicizumab in the HAVEN 3 Clinical Trial
Kiialainen A, Castaman G, Chang T, et al. Presented at NHF; August 1-8, 2020.
Hemophilia A and Mortality
Mortality in Congenital Hemophilia A - A Systematic Literature Review
Hay CRM, Nissen F, and Pipe SW. J Thromb Haemost. 2021;19(Suppl 1):6–20.
Establishment of a Framework for Assessing Mortality in Persons With Congenital Hemophilia A and Its Application to an Adverse Event Reporting Database
Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. J Thromb Haemost. 2021;19(Suppl 1):21–31.
Application of a Hemophilia Mortality Framework to the Emicizumab Global Safety Database
Peyvandi F, Mahlangu JN, Pipe SW, et al. J Thromb Haemost. 2021;19(Suppl 1):32–41.
A Systematic Review of Mortality Statistics and Causes of Death in People With Congenital Hemophilia A (PwcHA)
Hay C, Nissen F, and Pipe S. Presented at NHF; August 1-8, 2020.
A Contemporary Framework For Understanding Mortality in People With Congenital Hemophilia A (PwcHA)
Pipe S, Kruse-Jarres R, Mahlangu J, et al. Presented at NHF; August 1-8, 2020.
An Analysis of Fatalities in Persons With Congenital Hemophilia A Reported in the FDA Adverse Event Reporting System (FAERS) Database
De Ford C, Kuebler P, Shang A, et al. Presented at NHF; August 1-8, 2020.
Impact of Inhibitors on Hemophilia A Mortality in the United States
Walsh CE, Soucie JM, Miller CH, et al. Am J Hematol. 2015;90:400–405.
Real-World Experience
Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry
Poon MC, Lee A, Germini F, et al. Presented at ASH; December 9-12, 2023.
Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study – an Assessment of Baseline PROMIS®-29 Scores
Buckner TW, Daoud N, Lee L, et al. Presented at ASH; December 9-12, 2023.
Risk Factors for Joint Bleeding in Severe Hemophilia A and B: Analysis of the Community Counts Longitudinal Surveillance Cohort
Manco-Johnson M, Acharya S, Ahuja S, et al. Presented at ASH; December 9-12, 2023.
Emicizumab Prophylaxis in Haemophilia A With Inhibitors: Three Years Follow-up From the UK Haemophilia Centre Doctors' Organisation (UKHCDO)
Wall C, Xiang H, Palmer B, et al. Haemophilia 2023;29(3):743–752.
Emicizumab Prophylaxis in Severe Haemophilia A Without Inhibitors: Outcomes and Indications. From the UK Hemophilia Centre Doctors' Organisation
Hay C, Wall C, Xiang H, et al. Presented at EAHAD; February 7-10, 2023.
Surgeries and Procedures in People with Haemophilia A on Emicizumab Prophylaxis: Analysis from the ATHN 7 Haemophilia Natural History Study
Buckner TW, Carpenter SL, Daoud N, et al. Presented at EAHAD; February 7-10, 2023.
Bleeding Control Improves After Switching to Emicizumab: Real World Experience From 251 Children in the PedNet Registry
Van Der Zwet K, de Kovel M, Motwani J, et al. Presented at EAHAD; February 7-10, 2023.
Emicizumab Prophylaxis in People With Hemophilia A Aged ≥50 Years With Comorbidities: Experience From the ATHN 7 Hemophilia Natural History Study
Buckner TW, Daoud N, Lee L, et al. Presented at ISTH; June 24-28, 2023.
Real-World Safety of Emicizumab: Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
Nissen F, Jiang Y, Hiew HJ, et al. Presented at ASH; December 10-13, 2022.
Emicizumab and Females With Hemophilia A: Case Series from ATHN 7
Recht M, Daoud N, Lee L, et al. Presented at ASH; December 10-13, 2022.
Safety and Efficacy of Emicizumab in People With Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7)
Buckner TW, Carpenter SL, Kempton CL, et al. Presented at ISTH; July 9-13, 2022.